Repurposing drugs for the management of COVID-19
J Cusinato, Y Cau, AM Calvani… - Expert opinion on …, 2021 - Taylor & Francis
Introduction: The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 represents
a serious health issue worldwide, with more than 61 million cases and more than 1.4 million …
a serious health issue worldwide, with more than 61 million cases and more than 1.4 million …
[HTML][HTML] Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review
C Prodromos, T Rumschlag - New microbes and new infections, 2020 - Elsevier
Hydroxychloroquine (HCQ) has shown efficacy against coronavirus disease 2019 (COVID-
19) in some but not all studies. We hypothesized that a systematic review would show HCQ …
19) in some but not all studies. We hypothesized that a systematic review would show HCQ …
[HTML][HTML] PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response
A substantial proportion of patients who have recovered from coronavirus disease-2019
(COVID-19) experience COVID-19–related symptoms even months after hospital discharge …
(COVID-19) experience COVID-19–related symptoms even months after hospital discharge …
Mortality rates among COVID-19 patients hospitalised during the first three waves of the epidemic in Milan, Italy: A prospective observational study
A Giacomelli, AL Ridolfo, L Pezzati, L Oreni… - PloS one, 2022 - journals.plos.org
Introduction This paper describes how mortality among hospitalised COVID-19 patients
changed during the first three waves of the epidemic in Italy. Methods This prospective …
changed during the first three waves of the epidemic in Italy. Methods This prospective …
SARS-CoV-2 viremia and COVID-19 mortality: A prospective observational study
A Giacomelli, E Righini, V Micheli, P Pinoli… - PLoS …, 2023 - journals.plos.org
Background SARS-CoV-2 viremia has been found to be a potential prognostic factor in
patients hospitalized for COVID-19. Objective We aimed to assess the association between …
patients hospitalized for COVID-19. Objective We aimed to assess the association between …
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies
A Salimi-Jeda, S Abbassi, A Mousavizadeh… - International …, 2021 - Elsevier
More than a year after the SARS-CoV-2 pandemic, the Coronavirus disease 19 (COVID-19)
is still a major global challenge for scientists to understand the different dimensions of …
is still a major global challenge for scientists to understand the different dimensions of …
Drug repurposing strategies and key challenges for COVID-19 management
COVID-19 is a clinical outcome of viral infection emerged due to strain of beta coronavirus
which attacks the type-2 pneumocytes in alveoli via angiotensin-converting enzyme 2 …
which attacks the type-2 pneumocytes in alveoli via angiotensin-converting enzyme 2 …
Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review
V Gil Martinez, A Avedillo Salas, S Santander Ballestin - Pharmaceuticals, 2021 - mdpi.com
Due to the lack of an etiologic treatment for SARS-CoV-2 and the difficulties involved in
developing new drugs, some drugs already approved for other diseases or with efficacy …
developing new drugs, some drugs already approved for other diseases or with efficacy …
Directly acting antivirals for COVID-19: where do we stand?
The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has
now become a pandemic with no approved therapeutic agent. At the moment, the genomic …
now become a pandemic with no approved therapeutic agent. At the moment, the genomic …
Effect of immunosuppression maintenance in solid organ transplant recipients with COVID‐19: systematic review and meta‐analysis
A Karruli, S Spiezia, F Boccia… - Transplant Infectious …, 2021 - Wiley Online Library
Background The aim of this study was to assess the effect of continuing immune suppressive
therapy in solid organ transplant recipients (SOTR) with coronavirus disease 2019 (COVID …
therapy in solid organ transplant recipients (SOTR) with coronavirus disease 2019 (COVID …